NasdaqGM:IRONBiotechs
Expanded Phase 3 APOLLO Enrollment for Bitopertin in EPP/XLP Might Change The Case For Investing In Disc Medicine (IRON)
Disc Medicine announced that it has now randomized and dosed the last participant in its pivotal, expanded 183-patient Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, with top-line data expected in the fourth quarter of 2026 and an FDA decision anticipated by mid-2027.
The trial’s enlargement from 150 to 183 patients, driven by patient and physician demand, underlines meaningful engagement with a potential first disease-modifying therapy for...